Julia Y Tsang1, Sui-Ting Lai1, Yun-Bi Ni1, Yan Shao1, Ivan K Poon, Johnny S Kwan1, Chit Chow1, Ka-Ho Shea2, Gary M Tse3. 1. Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, NT, Hong Kong SAR. 2. Department of Pathology, Tuen Mun Hospital, Tuen Mun, NT, Hong Kong SAR. 3. Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Ngan Shing Street, Shatin, NT, Hong Kong SAR. garytse@cuhk.edu.hk.
Abstract
PURPOSE: SETD2 is one of the key epigenetic regulatory genes involved in histone modifications. Its alterations were potentially oncogenic and commonly found in cancers. Interestingly, SETD2 is one of the most frequent mutated genes found exclusively in phyllodes tumor of the breast (PT). However, little has been done to further characterize SETD2 alterations in PT. METHODS: In this study, we examined the alterations of SETD2 gene and protein expression in a large cohort of PTs. Their correlations with SETD2 downstream target, H3K36me3 expression, and clinicopathologic features in PT were also assessed. RESULTS: SETD2 mutation was found in 15.9% of our cases and was mostly predicted to be damaging mutations. Interestingly, SETD2 mutations were associated with lower H3K36me3 expression, particularly those with damaging mutations (p = .041). Neither SETD2 mutations nor H3K36me3 expression was associated with PT grading and other clinicopathological features. By contrast, the SETD2 protein expression cannot reflect its mutation status and showed a different trend of clinicopathological correlations from H3K36me3. CONCLUSIONS: Our findings may suggest a potential involvement of epigenetic regulation via SETD2 alterations and downstream H3K36me3 on PT development. SETD2 mutations may occur early in the pathogenic process of PTs and its loss per se may not be sufficient for progression to malignancy. Exclusive alterations of SETD2 in PT can be used as markers for the diagnosis of fibroepithelial lesions. The association of H3K36me3 with SETD2 mutations may also indicate the value of evaluation of H3K36me3 expression in the diagnosis of fibroepithelial lesions.
PURPOSE: SETD2 is one of the key epigenetic regulatory genes involved in histone modifications. Its alterations were potentially oncogenic and commonly found in cancers. Interestingly, SETD2 is one of the most frequent mutated genes found exclusively in phyllodes tumor of the breast (PT). However, little has been done to further characterize SETD2 alterations in PT. METHODS: In this study, we examined the alterations of SETD2 gene and protein expression in a large cohort of PTs. Their correlations with SETD2 downstream target, H3K36me3 expression, and clinicopathologic features in PT were also assessed. RESULTS: SETD2 mutation was found in 15.9% of our cases and was mostly predicted to be damaging mutations. Interestingly, SETD2 mutations were associated with lower H3K36me3 expression, particularly those with damaging mutations (p = .041). Neither SETD2 mutations nor H3K36me3 expression was associated with PT grading and other clinicopathological features. By contrast, the SETD2 protein expression cannot reflect its mutation status and showed a different trend of clinicopathological correlations from H3K36me3. CONCLUSIONS: Our findings may suggest a potential involvement of epigenetic regulation via SETD2 alterations and downstream H3K36me3 on PT development. SETD2 mutations may occur early in the pathogenic process of PTs and its loss per se may not be sufficient for progression to malignancy. Exclusive alterations of SETD2 in PT can be used as markers for the diagnosis of fibroepithelial lesions. The association of H3K36me3 with SETD2 mutations may also indicate the value of evaluation of H3K36me3 expression in the diagnosis of fibroepithelial lesions.
Entities:
Keywords:
H3K36me3; Immunohistochemistry; Phyllodes tumors of breast; SETD2; Sequencing
Authors: Jing Tan; Choon Kiat Ong; Weng Khong Lim; Cedric Chuan Young Ng; Aye Aye Thike; Ley Moy Ng; Vikneswari Rajasegaran; Swe Swe Myint; Sanjanaa Nagarajan; Saranya Thangaraju; Sucharita Dey; Nur Diyana Md Nasir; Giovani Claresta Wijaya; Jing Quan Lim; Dachuan Huang; Zhimei Li; Bernice Huimin Wong; Jason Yong Sheng Chan; John R McPherson; Ioana Cutcutache; Gregory Poore; Su Ting Tay; Wai Jin Tan; Thomas Choudary Putti; Buhari Shaik Ahmad; Philip Iau; Ching Wan Chan; Anthony P H Tang; Wei Sean Yong; Preetha Madhukumar; Gay Hui Ho; Veronique Kiak Mien Tan; Chow Yin Wong; Mikael Hartman; Kong Wee Ong; Benita K T Tan; Steven G Rozen; Patrick Tan; Puay Hoon Tan; Bin Tean Teh Journal: Nat Genet Date: 2015-10-05 Impact factor: 38.330
Authors: Andi K Cani; Daniel H Hovelson; Andrew S McDaniel; Seth Sadis; Michaela J Haller; Venkata Yadati; Anmol M Amin; Jarred Bratley; Santhoshi Bandla; Paul D Williams; Kate Rhodes; Chia-Jen Liu; Michael J Quist; Daniel R Rhodes; Catherine S Grasso; Celina G Kleer; Scott A Tomlins Journal: Mol Cancer Res Date: 2015-01-15 Impact factor: 5.852
Authors: Salvatore Piscuoglio; Charlotte Ky Ng; Melissa Murray; Kathleen A Burke; Marcia Edelweiss; Felipe C Geyer; Gabriel S Macedo; Akiko Inagaki; Anastasios D Papanastasiou; Luciano G Martelotto; Caterina Marchio; Raymond S Lim; Rafael A Ioris; Pooja K Nahar; Ino De Bruijn; Lillian Smyth; Muzaffar Akram; Dara Ross; John H Petrini; Larry Norton; David B Solit; Jose Baselga; Edi Brogi; Marc Ladanyi; Britta Weigelt; Jorge S Reis-Filho Journal: J Pathol Date: 2016-01-25 Impact factor: 7.996
Authors: Diego A Garcia-Dios; Dina Levi; Vandna Shah; Cheryl Gillett; Michael A Simpson; Andrew Hanby; Ian Tomlinson; Elinor J Sawyer Journal: Br J Cancer Date: 2018-01-09 Impact factor: 7.640
Authors: Julia Y S Tsang; Yau-Kam Hui; Michelle A Lee; Maribel Lacambra; Yun-Bi Ni; Sai-Yin Cheung; Cherry Wu; Ava Kwong; Gary M K Tse Journal: Sci Rep Date: 2018-03-01 Impact factor: 4.379